Restrictive and Liberal Transfusion Strategies in Intensive Care
Launched by UNIVERSITY OF EDINBURGH · Jul 21, 2009
Trial Information
Current as of June 04, 2025
Completed
Keywords
ClinConnect Summary
Anaemia is a common complication of critical illness and 40-50% of all patients in intensive care units (ICUs) receive blood transfusions. However, despite the perceived benefits of correcting anaemia, numerous non-randomised cohort studies and a system review suggest associations between blood transfusions and adverse patient outcomes. The only large randomised controlled trial comparing restrictive with liberal transfusion policies in critically ill patients (the "TRICC study") suggested a trend to greater morality at 30 days in the liberal transfusion group. However the TRICC study does ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient remains in the ICU after 96 hours (4 days) or more following ICU admission
- • The patient has required mechanical ventilation via an endotracheal tube or tracheostomy tube for 96 hours or more
- • The patient is expected to require ≥24 hours of further mechanical ventilation at the time of assessment
- • The patient is aged ≥55 years of age
- • The patient has a Hb value of 90g/L or less at the time of assessment
- Exclusion Criteria:
- • Patient with active bleeding at the time of screening
- • Patient with traumatic brain injury as presenting diagnosis
- • Patient with intracranial haemorrhage as presenting diagnosis
- • Patient not expected to survive the next 48 hours at the time of assessment.
- • Patient objects to RBC transfusion
- • Patient receiving concurrent treatment with erythropoietin or similar erythropoietic agent
- • Follow up is not feasible
- • Already enrolled in another RCT with similar clinical endpoints
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Dundee, , United Kingdom
Edinburgh, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Edinburgh, , United Kingdom
Stirling, , United Kingdom
Patients applied
Trial Officials
Timothy S Walsh, MBChB MD MSc
Principal Investigator
NHS Lothian
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials